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ABSTRACT
Background: The rising Caesarean section rate in the developing world implies that 
the incidence of placenta accreta might be on the increase and this might worsen the 
maternal mortality burden. 
Objective: To draw the attention of Obstetricians and other relevant professionals to 
this emerging but challenging trend.
Data Sources: Original research findings and reviews published in the English 
literature. Additional information was obtained from texts and electronic books such 
as CD ROMS.
Data Extraction: Online searches of electronic database (Medline, Pubmed and 
Embase), requests for reprints from corresponding authors and institutional/private 
subscriptions.
Data Synthesis: Information obtained was categorised accordingly. 
Conclusion: Optimal treatment of women with placenta accreta requires recognition of 
the clinical risk factors, accurate pre-operative diagnosis and meticulous planning to 
ensure safety at the time of delivery. In view of the rising incidence of this condition, and 
the absence of a highly reliable antenatal diagnostic method especially in developing 
countries, a high index of suspicion and advanced preparation is required to reduce 
its associated maternal morbidity and mortality.
INTRODUCTION
Placenta accreta is a rare and challenging complication 
of pregnancy associated with increased maternal 
morbidity and mortality , loss of reproductive organs 
and high demands on  meagre health resources 
(1 – 5).
 The incidence of placenta accreta in the developed 
world is said to have increased ten-fold in the past 50 
years (1, 4 – 5). This remarkable rise in its incidence 
has been largely attributed to the rising Caesarean 
section rate (1, 4 – 5).
 In Nigeria and other developing countries, an 
increasing caesarean section rate has been reported, 
indicating also that the incidence of placenta accreta 
may be on the increase (6-10). Placenta accreta may 
therefore further worsen the already bad maternal 
mortality situation the developing world. The 
purpose of this review is to draw the attention of 
Obstetricians, Sonologists, Obstetric Anaesthetists 
and Haematologists to this emerging but challenging 
trend.
DEFINITIONS AND PATHOLOGICAL BASIS
Placenta accreta is an abnormal adherence of the 
placenta to the underlying myometrium or serosa. If 
the placental villi are attached to, but do not invade 
the myometrium, the condition is referred to as 
placenta accreta. If the villi invade the myometrium, 
the condition is called placenta increta, and if the villi 
penetrate completely through the myometrium to 
the serosal surface of the uterus, the term placenta 
percreta is applied. The term placenta accreta is 
commonly used as a generic term to refer to all the 
three categories together (11).
 Soon after fertilisation and implantation, the 
maternal endometrium in response to increased levels 
of oestrogen and progesterone, undergoes a change 
in histology forming a thickened soft layer called 
decidua. This layer has three parts one of which is 
the decidua basalis, which forms beneath the area of 
the zygote implantation. Normally, the placenta villi 
do not invade beyond the deciduas basalis. Placenta 
accreta therefore occurs as a result of a decidua 
basalis defect in which the anchoring placental villi 
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are in direct contact with the myometrium instead of 
decidual cells. This abnormal adherence leads to none 
or incomplete separation of the placenta at the time 
of delivery and massive post-partum haemorrhage. 
Moreover, placenta percreta may result in invasion 
of adjacent pelvic organs such as the bladder and the 
gut (12).
INCIDENCE
The reported incidence of placenta accreta worldwide 
is extremely variable, ranging from 0.001% to 0.9% 
(4–5, 12, 13). The variability is due to the definition 
adopted for accreta (clinical or histopathologic 
diagnosis), the population studied and the time 
of the study (4, 13). Some studies based their 
definition or diagnosis of placenta accreta strictly 
on the histological criteria and as such reported 
lower incidence whereas the studies that combined 
clinical criteria with histology tended to report a 
higher incidence (1,4,13). The histological method 
is said to be the classic and more  objective method 
that firmly establishes the minimum incidence of 
placenta accreta (13).
 The histological diagnosis is however not perfect 
and is fraught with the following pitfalls:
• Post-partum histological examination of the 
placenta involves only samples of the placental 
surface and as such small parts that contain 
myometrial tissue may be missed. Moreover the 
accuracy of histological diagnosis even on using 
hysterectomy specimens is said to depend on the 
number of tissue blocks examined.
• Mild cases of placenta accreta diagnosed 
histologically might be clinically unnoticed 
(incidental findings)
• The increasing use of conservative management 
further makes the incidence harder to define, as 
no histology is available.
 It has therefore been suggested that strict 
histological criteria with total disregard of clinical 
criteria may not be appropriate (1, 4, 13, 14).
The clinical criteria for definition of placenta accreta 
include:
• Failure to find a cleavage plane for placenta at 
manual removal or Caesarean section leading to 





 It is however important not to confuse placenta 
accreta with simple retention of the placenta after 
birth, which is quite a common condition that is easily 
managed by conventional methods (13). It has also 
been observed that since placenta accreta is a clinical 
obstetric emergency and its management is based 
on clinical diagnosis, clinical criteria for definition 
should not be ignored (4,13).
 The combination of histological and clinical criteria 
is therefore more appropriate (4,13 ).
 The incidence of placenta accreta in the last five 
decades has been observed to be on the increase (1, 
4, 5, 12,15). The placenta accreta variant is much 
more common than the other more invasive variants 
accounting for 75 – 78% of all cases. Placenta increta 
and percreta account for 17% and 5 – 7% of cases 
respectively (11). 
AETIOLOGY AND RISK FACTORS
The aetiology of placenta accreta is not known but 
many speculations and theories have been proposed 
during the years. These include lack of progesterone, 
local inflammation, lack of space for placenta to 
expand and bleeding in the early pregnancy causing 
an organisation of blood clot with local fibrosis (12, 
13). The contemporary scientific view however is 
that the pathogenesis leading to the lack of decidua 
basalis may be due to local trauma, progressive 
vascular endothelial damage which occurs with aging, 
inappropriate decidual reaction in the lower segment 
and genetic factors (2,12,13,16). The possibility of 
a genetic cause for placenta accreta is supported 
by the observation that its recurrence rate may be 
as high as 16% and that a significant number of 
primiparous women without any known risk factors 
may be affected (13). The reported risk factors for 
placenta accreta include placenta praevia, previous 
Caesarean section, advanced maternal age (≥35 years), 
previous uterine curettage, previous endometritis, 
Asherman’s syndrome, grandmultiparity, multiple 
pregnancy, pelvic irradiation, previous trophoblastic 
disease, previous myomectomy, submucuous fibroid, 
manual removal of placenta, smoking, female foetus, 
abnormally elevated second trimester alpha foetal 
protein and free B-human chorionic gonadotrophin 
(15 – 17).
 Placenta praevia and previous Caesarean section 
act synergistically to further increase the risk of 
placenta accreta. When placenta praevia is present 
without previous uterine surgery, the risk of accreta 
is 10%. On the other hand the risk of placenta accreta 
is 12% with a history previous Caesarean section(s) 
without placenta praevia. However, the risk increases 
sharply to as high as 25% with a combination of one 
previous Caesarean section and placenta praevia. The 
risk further rises proportionately with the number 
of previous Caesarean sections, hence it increases to 
50% after two Caesarean sections and 67% after four 
Caesarean sections (14).
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PRESENTATION
Placenta accreta can be present at any gestation from 
first trimester to term. It may be discovered during 
dilatation and curettage when massive bleeding 
occurs due to placental invasion of the myometrium. 
Individuals who are at risk of placenta accreta at term 
are also at risk for it in the first trimester (18).
 The most common clinical presentation of 
placenta accreta is post-partum haemorrhage 
associated with a retained placenta (11 - 12). It may 
be observed for the first time at caesarean section 
(12).
 Other modes of presentation include antepartum 
haemorrhage, acute abdomen and shock from 
ruptured uterus and painless haematuria if the 
bladder is involved ( 11, 12, 14, 18).
ANTENATAL DIAGNOSIS
Antenatal diagnosis of placenta accreta is difficult 
but very important as it represents a possibility for 
accurate planning and preparation for delivery. It also 
creates an opportunity for multidisciplinary input in 
the management of the condition (12, 14, 19, 20).
 If pregnancy is complicated by any of the 
risk factors earlier mentioned, transabdominal 
or transvaginal ultrasound, colour flow Doppler 
ultrasonography and magnetic resonance imaging 
may be used.
ULTRASOUND FEATURES
Low Lying Gestational Sac: In the first trimester, the 
ultrasound feature that is suggestive of placenta 
accreta is a low lying gestational sac that appears to be 
attached to the anterior wall of the uterus. The usual 
location of a normal early gestation is in the fundus 
or very occasionally in the lower segment where it is 
surrounded by thick myometrium on all sides.
Loss of the clear zone:  The usual dark line (sonoluscent 
space) between the myometrium and the placenta is 
thought to represent the dilated vessels of the decidua 
basalis. Since the decidua basalis is absent in placenta 
accreta, it has been suggested that the absence of this 
hypoechoic line suggests placenta accreta (11,20–25). 
Abnormal placental adherence is thus thought to 
be associated with focal or complete loss of the 
hypoechoic line, such that the echogenicity of the 
placenta appears to be contiguous with the bladder 
wall. This line however said to be absent in many 
normal patients with anterior placentas. Its sensitivity 
and positive predictive value is low (20,  23).
Placental  Lakes (Lacunae): Placental lacunae are 
multiple linear, irregular vascular spaces within the 
placenta. Such lacunae need not be near the area 
of invasion for the diagnosis to be made  (20,23).
The likelihood of placenta accreta increases with 
the number of the lacunae. The lacunae give a 
‘moth-eaten’ appearance to the placenta  (11,20-25). 
Not all large sinuses or vessels are associated with 
placenta accreta. Those not associated with abnormal 
adherence are smooth in contour and quite round 
(20,  23). The presence of placenta lacunae is said to 
be more sensitive for diagnosis than the loss of the 
hypoechoic space  (20,  23, 25).
Bladder border: The border between the bladder 
and myometrium is normally highly echogenic 
and smooth. In placenta accreta interruption of the 
posterior bladder wall-uterine interface occurs such 
that a continuous echoluscent line appears instead 
of the echogenic border. This feature is said to be 
highly specific. It is however poorly sensitive as 
interruptions are not present in many patients with 
placenta accreta ( 21 – 25).
 Generally speaking, ultrasonography has a 
variable sensitivity of 35 – 93% for diagnosing placenta 
accreta. It is limited in obese women and in evaluating 
extra uterine extent and fundal or posterior placenta 
accreta (20,  19 – 24).
The role of colour doppler: Colour Doppler will not only 
show the placental sinuses but their transversing 
through the uterine wall. It will also demonstrate 
turbulent blood flow extending from the placenta 
into the surrounding tissues  (20, 23).
 The sensitivity and specificity of colour Doppler 
imaging for diagnosing placenta accreta are reported 
to be 82.4 – 100% and 92 – 96.8%, respectively (3, 20, 
23-24). The advantages of colour Doppler compared to 
gray-scale ultrasonography are improved specificity 
and better assessment of the depth of myometrial and 
serosal invasion.
Magnetic Resonance Imaging (MRI): The role of magnetic 
resonance imaging in the diagnosis of placenta accreta 
remains controversial. It may however be utilised 
if gray scale ultrasonography and colour Doppler 
are not satisfactory and the placenta is posteriorly 
located (20, 23).
 It has been suggested that the use of gadolinium-
based contrast enhancement will add to the specificity 
of MRI in the diagnosis of placenta accreta because 
it more clearly delineates the outer placental surface 
relative to the myometrium and eliminates the 
confusion between heterogeneous signals thought to 
be within the placenta from those caused by maternal 
blood vessels (24).
Biochemical Markers: It has been reported that many 
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women with placenta accreta will have an otherwise 
unexplained elevation of the maternal serum alpha-
fetoprotein, free B-human chorionic gonadotrophin 
and creatine kinase (5, 12). Accordingly, elevation of 
these biochemical markers in the second trimester 
co-existing with placenta praevia and/or previous 
caesarean section should raise concerns about the 
possibility of placenta accreta.
 There is as yet no diagnostic technique that 
affords the clinician 100% assurance of either ruling 
in or ruling out the presence of placenta accreta (5, 
20,23). A high index of suspicion is still required in 
the diagnosis of the condition. In settings where 
the above-mentioned imaging and biochemical 
modalities are not available, all cases of placenta 
praevia in women with one or more previous 
caesarean sections should be managed as placenta 
accreta until proven otherwise.
MANAGEMENT
If an antenatal diagnosis or strong suspicion of 
placenta accreta is made;
• The patient should be counselled about 
the likelihood of hysterectomy and blood 
transfusion.
• At least 8 – 12 units of cross-matched blood should 
be made available.
• If the personnel and equipment required for the 
management of such cases are lacking, referral to 
centres with such capacity should be made,
• A preoperative anaesthesia assessment should 
be obtained, specific preoperative preparations 
such as autologous blood donation, arterial and 
central line insertion or hypogastric artery balloon 
placement can be undertaken in preparation of 
surgery.
• The Senior Obstetrician with vast experience in 
obstetric hysterectomy must be present at surgery. 
(A case of placenta accreta is not the one to be left 
to the Senior Registrar or junior Residents).
• Cell saver technology should be considered if 
available.
Treatment options for placenta accreta include 
surgical removal of the uterus (and the involved 
structures in some cases of placenta percreta) and 
conservative therapy (3-5,12,14,26).
SURGICAL REMOVAL OF THE UTERUS 
(HYSTERECTOMY)
Hysterectomy is the conventional treatment for 
placenta accreta. Placenta accreta has become the 
most common indication for emergency peripartum 
hysterectomy in developed countries (30-32).  With 
rising caesarean section rates in Nigeria and other 
developing countries, placenta accreta may become 
superimposed on the preventable indications for 
peripartum hysterectomy such as ruptured uterus 
and uterine atony (8-10). Peripartum hysterectomy 
may be total or subtotal. A subtotal hysterectomy may 
be acceptable where maternal instability mandates a 
more expeditious procedure (26). It may be however 
associated with continued bleeding from the cervical 
branch of the uterine artery which supplies the 
lower uterine segment and cervix. Some authorities 
therefore favour total abdominal hysterectomy 
especially in cases of placenta praevia accreta.
 When the decision has been made prior to 
caesarean section to perform hysterectomy, the intact 
placenta should be left in place following delivery 
of the foetus through a classical uterine incision. 
The uterine incision should be closed or over sewn 
circumferentially before proceeding to hysterectomy. 
This reduces blood loss associated with separation 
of the adherent placenta. 
 Other measures that help to prevent massive 
blood loss during hysterectomy and as such keep the 
operative site sufficiently dry to carry out a careful 
dissection include balloon occlusion of the aorta or 
hypogastric vessels, and application of tourniquet 
around the uterine  cervix (33).
 Caesarean hysterectomy is associated with 
significant maternal morbidity due to urological 
injury, fistula formation, sepsis, adnexal removal, 
massive blood transfusion and devastating 
psychological consequences (28). Nevertheless, 
it remains the mainstay of treatment for severe 
intractable postpartum bleeding and should not 
be delayed until the patient has deteriorated to a 
moribund state (3,12,14,28).
 In cases of placenta percreta with extension to 
contiguous structures, surgery may involve resection 
of such structures such as the bladder or bowel and 
this may further worsen the morbidity (34).
Conservative Treatment: Conservative treatment has 
the advantage of preserving fertility and menstrual 
function, and reducing blood loss (3, 12,26, 35-37). It 
is however only possible in the presence of a stable 
haemodynamic condition and adequate technical 
support (12, 26). This treatment modality should be 
considered whenever feasible in environments such 
as ours where there is a strong desire for large family 
size and aversion to hysterectomy (41). Conservative 
treatment may however be complicated by sepsis, 
secondary haemorrhage and treatment failure (26).
Conservative approaches include:
Uterine Packing:  This involves tight packing of the 
uterus with gauze after removing the placenta. 
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Following good and uniform packing of the uterine 
cavity, the abdomen is closed up under careful 
monitoring with adequate fresh blood and broad-
spectrum antibiotic cover. The pack can then be 
removed 24 to 36 hours later. This treatment modality 
for the treatment of post-partum haemorrhage was 
previously abandoned because it was considered as 
an unphysiological procedure and was associated 
with concealed haemorrhage (28). New interest has 
been however aroused recently in its favour (28).
Uterine and internal iliac arteries ligation: Uterine 
artery ligation may be used to control bleeding from 
the uterus as the uterine arteries supply 90% of the 
uterine blood flow. The technique of its ligation has 
been described as a potentially easier alternative to 
hypogastric artery ligation (28). A stitch is passed 
into the myometrium 2 – 3 centi metre medial to the 
artery at the same level as a transverse lower segment 
incision would be made for caesarean section. The 
suture is brought out through the posterior aspect 
of the uterus and then brought anteriorly again 
through the broad ligament at the same level before 
tying. Care must be taken to exclude the ureter in the 
stitch. If this procedure proves time consuming and 
the patient’s condition is deteriorating, it should be 
abandoned in favour of hysterectomy.
 The use of bilateral internal iliac artery ligation 
for arresting active placental bed haemorrhage is 
becoming less popular because it does not result in the 
complete cessation of bleeding due of the extensive 
pelvic collateral circulation. Moreover, the technical 
problems encountered in the procedure are enormous 
(28).
LEAVING THE PLACENTA IN SITU WITH 
OR WITHOUT ADJUVANT TREATMENT 
The placenta may be left in situ with adjuvant treatment 
such as methotrexate, uterine artery embolisation, or 
sulprostone (26,35,38-39).
 Methotrexate is a cytotoxic drug, which affects 
the placental tissue by decreasing its vascularity 
thereby leading to its necrosis. The sensitivity 
of trophoblastic tissue to methotrexate is well 
documented by its use in gestational trophoblastic 
disease. It can be administered intramuscularly at a 
dose of 50mg/m2 per week x 6 doses (35). The use of 
methotrexate requires serial ultrasound and serum 
BHCG assays as well as frequent blood counts, liver 
and renal function tests to monitor its effectiveness 
and safety (38).
 Some reports have shown the success of uterine 
artery embolisation as an adjuvant procedure (28). 
Sulprostone is well known uterotonic agent used in 
case of post-partum haemorrhage (26).
 In contrast to the use of adjuvant treatment, 
some cases have had no additional treatment after 
leaving the placenta in situ and still had successful 
outcomes. Published reports do not currently prove 
the superiority of the adjuvant treatment (3, 26).
THE USE OF VASOPRESSIN
Vasopressin is a nano-peptide produced by the 
supraoptic and paraventricular nuclei of the 
hypothalamus. It has a potent vasoconstrictor effect 
on the arterioles throughout the human body. This 
effect has been widely used by gastroenterologists 
to arrest massive bleeding from oesophageal varices 
(28). It can be diluted with saline and injected at the 
bleeding sites of the placental bed. It should be used 
before massive haemorrhage has occurred since 
uterine vasculature in massive obstetric haemorrhage 
is non-responsive to vasoconstrictor agents (28). The 
use of vasopressin, if effective, is superior to other 
conservative measures since bleeding stops almost 
immediately (28).
OTHER CONSERVATIVE APPROACHES
Other conservative treatment modalities include 
localised resection and uterine repair, B-Lynch uterine 
compression suture, over sewing the uterine defect, 
blunt  curettage of the uterine cavity and argon beam 
coagulation of the placental site (12, 14,39,44,45).
COMPLICATIONS OF PLACENTA ACCRETA
The most important complication of placenta accreta 
is haemorrhage (3-4, 12,33,43). It can be massive and 
life threatening except in conditions of small focal 
placenta accreta. The massive haemorrhage can lead to 
cardiovascular collapse and shock, acute renal failure, 
Sheehan’s syndrome, disseminated intravascular 
coagulopathy, massive blood transfusion, loss of 
reproductive organs and  maternal death (12, 14,33). 
Maternal death associated with placenta accreta is put 
at 7% (12, 33). This may be even higher in developing 
countries. The complications related to treatment of 
the condition include injury to the bladder; ligation 
or injury to the ureters, fistula formation, sepsis, 
treatment failure and complications from massive 
blood transfusion (12,14,33). Other complications 
related to degree of uterine wall invasion include 
uterine rupture and extension to adjoining structures 
such as the bladder and bowel (12,34).
 The reported perinatal complications of placenta 
accreta include prematurity, small for gestational 
age and increased perinatal mortality (43). The 
adverse perinatal outcomes are thought to result 
from pathological implantation of the placenta that 
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interferes with normal placental function and leads 
to abnormal fetal growth (43).
 The average number of units of blood required 
for transfusion in cases of placenta accreta is put at 6.6 
units with some cases requiring over 20 units of blood  
(33). This massive transfusion classically illustrates 
the high demand this condition may have on the 
meagre health resources of developing countries 
where homologous blood is often not available due 
to difficulties in recruiting and screening donors and 
in the collection and storage of blood (42).
Practice Points
• In the presence of  risks factors;  Sonologists should 
look for and report the presence or absence of the 
ultrasound features discussed.
• In the absence of reliable ultrasound diagnosis 
placenta praevia in women with one or more 
previous caesarean sections should be managed 
as if they have placenta accreta until proven 
otherwise.
• Placenta accreta is a long term complication of 
multiple caesarean sections and as such women 
undergoing such procedure should be counselled 
about the complication and the need for prevention 
through family planning.
• If the personnel and materials required for the 
management of suspected or diagnosed cases 
are lacking, referral to centres with such capacity 
should be made.
• A senior obstetrician with experience in obstetric 
hysterectomy must be present at surgery for 
suspected placenta accreta.
• The incidence of placenta accreta may increase 
further in the coming decades and  as such 
residents in obstetrics must be trained to be able to 
carry out such a life saving procedure as caesarean 
hysterectomy.
• The average number of units of blood transfused 
in cases of accreta is 6.6 units with some cases 
requiring over 20 units of blood. At least 8 – 12 
units of blood must be made available in suspected 
cases of placenta accreta. There is need to improve 
the blood transfusion services of many obstetric 
centres in order to meet up with this challenge.
• When a decision has been made prior to caesarean 
section to carry out hysterectomy, the intact 
placenta should be left in situ following the 
delivery of the foetus through a classical uterine 
incision.
RESEARCH POINTS
• There is generally a need for a large study on 
placenta accreta in the developing countries 
especially its trend with rising caesarean section 
rates and advanced maternal age.
• There is need for a large multicentre trial 
comparing the conventional extirpative with 
conservative management. Although there are 
several cases reports of successful conservative 
treatment, they cannot be used to evaluate benefits 
and disadvantages of each therapeutic strategy in 
a comparative manner.
• A similar study is also required to demonstrate if 
adjuvant therapy in cases where placenta is left 
in situ has any advantages over those without 
adjuvant treatment. This is particularly important, 
as a cytotoxic drug such as methotrexate with 
toxic side effects should not be used if it confers 
no benefit.
In conclusion, optimal treatment of women with 
placenta accreta requires recognition of the clinical 
risk factors, accurate pre-operative diagnosis and 
meticulous planning to ensure safety at the time of 
delivery.
 In view of the rising incidence of this condition, 
and the absence of a highly reliable antenatal 
diagnostic method especially in developing countries, 
a high index of suspicion and advance preparation is 
required to reduce its associated maternal morbidity 
and mortality. Moreover, the need for peripartum 
hysterectomy might be on the increase and as such 
Residents in obstetrics who carry out most of the 
caesarean sections should be adequately trained to 
perform peripartum hysterectomy.
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